Silk Road Medical Enters Definitive Deal To Be Acquired By Boston Scientific For $27.50 In Cash Per Share, Representing An Equity Value Of Approximately $1.26B
Portfolio Pulse from Benzinga Newsdesk
Silk Road Medical has entered a definitive agreement to be acquired by Boston Scientific for $27.50 per share in cash, valuing the deal at approximately $1.26 billion. This price represents a 38% premium to Silk Road Medical's 60-day volume-weighted average share price. Upon completion, Silk Road Medical will become a wholly-owned subsidiary of Boston Scientific.
June 18, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific has agreed to acquire Silk Road Medical for $27.50 per share, valuing the deal at approximately $1.26 billion. Silk Road Medical will become a wholly-owned subsidiary of Boston Scientific upon completion.
The acquisition of Silk Road Medical could be seen as a strategic move for Boston Scientific, potentially enhancing its product portfolio and market position, which may positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Silk Road Medical is set to be acquired by Boston Scientific for $27.50 per share, a 38% premium over its 60-day volume-weighted average share price. The acquisition values Silk Road Medical at approximately $1.26 billion.
The acquisition price represents a significant premium, which is likely to drive Silk Road Medical's stock price up in the short term as investors react positively to the premium offer.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100